Contraception access statistics: unintended pregnancy and the gaps that remain

She had run out of pills on a Tuesday. The pharmacy said the refill was denied because her plan required a new prescription after 12 months, and her annual exam was not until next month. By Friday she was calculating cycle days on her phone and asking me whether missing three days meant she needed emergency contraception. She did not need a lecture on adherence. She needed a system that did not treat continuous contraception as optional.

That is the gap this article is about. In 2019, 41.6% of pregnancies in the United States were unintended, according to the CDC. The share has edged down since 2010, but more than four in ten pregnancies still arrive earlier than wanted or when none was wanted. Method choice and clinic capacity sit between that headline and a patient's options. So do geography and insurance continuity.

Here is what recent data show about unintended pregnancy, method use, contraceptive deserts, cost and insurance, over-the-counter oral contraception, typical-use versus perfect-use failure rates, and Title X clinic capacity.

Unintended pregnancy in numbers

The CDC defines an unintended pregnancy as one that is unwanted (no children, or no more children, were desired) or mistimed (it occurred earlier than desired). That definition is clinical and blunt. It does not capture ambivalence or pregnancies that become wanted later. It does give a national yardstick reporters and clinicians use.

Using methods published in 2023, CDC's National Center for Health Statistics estimated that the percentage of U.S. pregnancies that were unintended declined from 43.3% in 2010 to 41.6% in 2019. The rate of unintended pregnancy fell by 15% over the same period, from 42.1 per 1,000 females aged 15-44 in 2010 to 35.7 in 2019. The overall pregnancy rate also declined, from 97.3 to 85.6 per 1,000 females aged 15-44.

Those are real gains, not a solved problem. Four in ten pregnancies still begin without intent, and the burden is uneven. Rates have historically been higher among adolescents and young adults, women with lower incomes, and women of color. Those patterns track method access, insurance continuity, and clinic proximity more than preference. Older "nearly half" estimates still circulate from earlier years; the NCHS 2010-2019 series is the most recent national share and rate I trust. Unintended pregnancy also collides with other outcomes we track, including pregnancy loss statistics and delayed prenatal care.

Contraceptive use by method

In 2022-2023, 54.3% of females ages 15-49 in the United States were currently using a contraceptive method, according to the National Survey of Family Growth as reported by NCHS. That figure is a snapshot of the month of interview. About 45.8% were not currently using contraception; 22.4% had never had intercourse or had not had sex in the past three months. Others were pregnant, postpartum, seeking pregnancy, or nonusers for other reasons.

Among all females ages 15-49, the most common current methods were female sterilization (11.5%), oral contraceptive pills (11.4%), long-acting reversible contraceptives or LARCs (10.5%), and the male condom (7.1%). Within LARCs, IUDs accounted for 8.1% and implants for 2.5%. Male sterilization (partner vasectomy) was the current method for 5.6% of females. Injectables, rings, or patches together were 2.3%; fertility awareness-based methods were 2.0%; withdrawal was 3.4%.

Age patterns are sharp. Female sterilization rises with age: about 26.4% of women ages 40-49 versus 11.9% of women ages 30-39. Pill use is higher among women 20-29 (16.8%) and lower among women 40-49 (6.9%). LARC use peaks in the 20s and 30s (13.8% and 12.4%) and is lower among teens (4.6%). Race and education gaps remain: current pill use was higher among White non-Hispanic females (14.1%) than among Hispanic (9.1%) or Black non-Hispanic (6.7%) females, and LARC use was lower among Black females (8.1%) than White females (11.6%). Among women ages 22-49, female sterilization fell with higher education (27.4% with no high school diploma or GED versus 6.0% with a bachelor's degree or higher).

Method mix is not the same as method preference. Some patients want a LARC and cannot find a same-day inserter. Some want the pill and cannot keep a continuous supply. Some use condoms because they also need STI protection. For context on infection risk, see our summary of STI statistics in women.

Contraceptive deserts

Access is geographic as well as financial. Power to Decide defines contraceptive deserts as counties where the number of health centers offering the full range of contraceptive methods is not enough to meet the needs of women eligible for publicly funded contraception, using a benchmark of at least one full-range health center for every 1,000 women in need.

By that measure, more than 19 million women of reproductive age who need publicly funded contraception live in contraceptive deserts. About 1.2 million live in a county without a single health center offering the full range of methods. "Full range" means sites that offer IUDs and implants on site along with most other FDA-approved methods such as pills and injectables as well as rings, patches, or emergency contraception, not a pharmacy that stocks condoms and one pill brand.

The definition is deliberately narrow. It does not count private clinicians who never advertise publicly funded care, and it does not measure wait times or transportation. Power to Decide notes that women who are not eligible for publicly funded contraception still rely on the same health centers for privacy or convenience. The 19 million figure is a floor for publicly funded need, not a ceiling on who feels the shortage. In clinic notes it looks ordinary: a two-hour drive for an IUD, or a missed Depo shot because clinic hours conflict with shift work. The pattern parallels maternity care deserts. If you are between methods, our ovulation calculator and period calculator can help with cycle timing. They are not substitutes for a reliable method.

Cost and insurance coverage

Under the Affordable Care Act, most private health plans must cover FDA-approved contraceptive methods and related counseling without patient cost-sharing when care is obtained in network. KFF summarizes the federal rule simply: most private plans cover recommended contraceptive methods as preventive services without copays, coinsurance, or deductibles, with limited exceptions such as grandfathered plans and certain employer religious or moral objections under rules that have shifted across administrations.

On paper, that should make prescription contraception free for most insured women. In practice, gaps persist. In KFF's reporting, one in four privately insured contraceptive users (24%) say they paid out of pocket for some or all of their contraception because their plan did not cover the full cost. Reasons include grandfathered plans, employer objections, out-of-network care, and brand-name products when a plan prefers a generic.

Awareness is another gap. Among women of reproductive age, less than half (43%) know that plans are required to cover all FDA-approved prescribed contraceptives, according to KFF. Among women with private insurance, only 44% were aware that most plans must pay the full cost of birth control. State law fills some holes: KFF notes that 31 states and D.C. require state-regulated plans to cover contraceptives, and 19 states and D.C. prohibit cost sharing, but those rules do not automatically reach self-funded employer plans under federal ERISA rules.

Pharmacist prescribing is authorized in many states, but consultation fees are often not covered. Uninsured patients still depend on Title X or Medicaid, and on federally qualified health centers. These mechanics sit inside the wider women's healthcare access gap: insurance on a card is not the same as a method in hand this month.

Over-the-counter oral contraception

On July 13, 2023, the FDA approved Opill (norgestrel) tablets for nonprescription use. It is the first daily oral contraceptive approved in the United States without a prescription. Opill is a progestin-only pill. Combined estrogen-progestin pills remain prescription-only. The FDA's rationale was that nonprescription availability may reduce barriers for people who cannot easily see a clinician, and that daily oral contraception used as directed is expected to be more effective than other nonprescription methods currently available for pregnancy prevention.

Opill became available in stores and online in 2024. KFF reported a suggested retail price of $19.99 for a one-month supply or $49.99 for a three-month supply. Among people who said they were likely to use an OTC oral contraceptive, four in ten (39%) would be willing to pay $1-$10 per month, and 11% would not be willing to pay anything. A third (34%) would pay $11-$20, roughly Opill's monthly sticker price.

Insurance coverage for OTC contraception without a prescription remains uneven. Federal rules require most private plans to cover prescribed contraceptives without cost sharing, but plans typically still require a prescription to trigger payment, even for shelf products. KFF has tracked a small group of states that require state-regulated private plans and/or Medicaid to cover at least some OTC contraception without a prescription. Elsewhere, Opill is often a cash purchase. Clinically, progestin-only pills demand tight daily timing, and the FDA notes that oral contraceptives do not protect against HIV or other sexually transmitted infections. OTC access expands one lane; it does not replace clinic capacity for IUDs, implants, or sterilization.

Typical use versus perfect use

Failure rates are where counseling either builds trust or quietly misleads. "Perfect use" assumes a method is used consistently and correctly every time. "Typical use" reflects real-world use, including missed pills, late injections, broken condoms, and gaps between packs. Both numbers are usually the percentage of women who become pregnant within the first year of use.

According to CDC summaries of contraceptive effectiveness, typical-use failure rates include approximately 0.1% to 0.4% for hormonal IUDs, 0.8% for the copper IUD, 4% for the injectable, 7% for combined and progestin-only pills as well as the patch and ring, 13% for the male (external) condom, and about 21% for the female (internal) condom and spermicides.

Perfect-use rates are substantially lower for methods that depend on daily or per-act user action. Classic effectiveness tables used in CDC contraceptive guidance, drawn from Contraceptive Technology, place perfect-use first-year failure near 0.3% for oral contraceptives and about 2% for male condoms. LARC perfect-use and typical-use rates barely diverge because there is little room for daily user error once the device is in place.

That gap is the clinical story. A pill that is more than 99% effective with perfect use becomes roughly 93% effective with typical use (about 7 pregnancies per 100 women in a year). Condoms move from very effective with perfect use to a 13% typical-use failure rate. IUDs and implants stay under 1% either way. I do not present perfect-use numbers as a character test. People miss pills when packs run out, when work shifts rotate, or when a pharmacy delay stretches a weekend into a week. KFF has reported that more than one third of oral contraceptive users have missed taking their birth control because they could not get the next supply on time.

Method counseling should match the patient's actual life. Someone who can take a daily pill on time may do well on oral contraceptives; someone with irregular hours or prior refill gaps may get better real-world protection from a LARC. Fertility-awareness methods can work for carefully trained users, but they are unforgiving when cycles are irregular. Our cycle length calculator helps patients see that variation.

Title X clinic capacity

Title X is the only federal program dedicated solely to family planning and related preventive services. It is the backbone under many of the health centers that keep counties off the darkest parts of the contraceptive desert map.

According to the HHS Office of Population Affairs' 2023 Family Planning Annual Report, Title X grant recipients served nearly 2.8 million unique clients in 2023. That was a 7% increase from 2022 and an 80% increase from 2020, when pandemic disruption and prior program rules had sharply reduced volume. Providers logged 4.3 million family planning encounters at 3,853 service sites across all 50 states, D.C., and several U.S. territories and freely associated states.

Who those clients are matters as much as the headcount. OPA reported that 60% of clients had family incomes below 101% of the federal poverty level and received services at no charge; 23% had incomes between 101% and 250% of poverty and received discounted care. Twenty-seven percent of Title X clients were uninsured, more than three times the national uninsured rate for U.S. adults cited in the same summary. Among clients who used insurance, 67% relied on public coverage. Eighty-five percent of clients were women. Nearly 36% identified as Hispanic or Latino, and 19% reported limited English proficiency.

OPA reported that 72% of all clients used a contraceptive method for family planning, including nearly 71% of female clients. The program also delivered substantial STI and cancer screening volume in 2023: roughly 1.34 million chlamydia tests, 1.57 million gonorrhea tests, 735,000 syphilis tests, 984,000 confidential HIV tests, and 461,000 cervical cancer screenings. Title X funding accounted for only 17% of grant recipients' total revenue; the rest came mostly from Medicaid and other third-party payers (56%) and other public sources (27%). An 80% rebound from 2020 is encouraging. It does not mean every desert county gained a full-range site.

NSFG data from 2022-2023 add a population-level backdrop: only 35.7% of females ages 15-49 received any family planning service in the prior 12 months, and 23.5% received a birth control method or prescription. For clinicians and journalists, the usable conclusion is narrow. Unintended pregnancy remains common. Method use is widespread but uneven. Deserts, cost-sharing gaps, and refill friction convert highly effective methods into typical-use failures. OTC progestin-only pills expand one lane of access. Title X is rebuilding but still serving people private insurance never fully reaches. Each number above has a named primary source next to it for a reason.

Frequently asked questions about contraception access and unintended pregnancy

What percentage of U.S. pregnancies are unintended?

According to the CDC, 41.6% of U.S. pregnancies were unintended in 2019, down from 43.3% in 2010. The unintended pregnancy rate declined 15% over that period, from 42.1 to 35.7 pregnancies per 1,000 females aged 15-44. Older "nearly half" figures usually reflect earlier years and should be dated when cited.

What are the most common contraceptive methods in the United States?

NCHS data from the 2022-2023 National Survey of Family Growth show that 54.3% of females ages 15-49 were currently using contraception. The most common methods were female sterilization (11.5%), oral contraceptive pills (11.4%), long-acting reversible contraceptives (10.5%), and the male condom (7.1%). Method mix varies by age, race and Hispanic origin, and education.

What is a contraceptive desert?

Power to Decide defines contraceptive deserts as counties where health centers offering the full range of contraceptive methods are too few to meet the needs of women eligible for publicly funded contraception: less than one full-range center per 1,000 women in need. More than 19 million women in need live in these counties; about 1.2 million live in a county with no full-range center at all.

Does insurance cover birth control at no cost?

Most private plans must cover FDA-approved prescribed contraceptives without cost sharing under the Affordable Care Act, with limited exceptions. KFF reports that 24% of privately insured contraceptive users still pay out of pocket for some or all of their method. Over-the-counter products such as Opill are often not covered unless a prescription is issued or a state rule requires OTC coverage.

How effective is the birth control pill with typical use?

CDC estimates place the typical-use failure rate for combined and progestin-only pills at about 7% in the first year (roughly 7 pregnancies per 100 women). With perfect use, failure is far lower (on the order of 0.3% in classic Contraceptive Technology tables cited in CDC guidance). IUDs and implants remain under 1% with both typical and perfect use.

How many people does Title X serve?

Title X served 2.8 million unique clients in 2023 across 3,853 service sites and 4.3 million encounters, according to the HHS Office of Population Affairs. That was up 7% from 2022 and 80% from 2020. Sixty percent of clients had incomes below 101% of the federal poverty level, and 27% were uninsured.